Christine L. Talarico

Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression

Susan Swindells, Jaime Andrade‐Villanueva, Gary Richmond et al. · New England Journal of Medicine · 2020 · 565 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Potent and Selective Inhibition of Human Cytomegalovirus Replication by 1263W94, a Benzimidazole <scp>l</scp> -Riboside with a Unique Mode of Action

Karen K. Biron, Stanley C. Chamberlain, Steven S. Good et al. · Antimicrobial Agents and Chemotherapy · 2002 · 364 citations · Full text

Life Sciences, Medicinal Chemistry, Pharmacology +17

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

Edgar T. Overton, Gary Richmond, Giuliano Rizzardini et al. · The Lancet · 2020 · 364 citations

Pharmacy, Pharmacology, Pharmacotherapy +15

Analysis Of The Ul97 Phosphotransferase Coding Sequence In Clinical Cytomegalovirus Isolates And Identification Of Mutations Conferring Ganciclovir Resistance

Szu‐Yi Chou, Alejo Erice, M. Colin Jordan et al. · The Journal of Infectious Diseases · 1995 · 243 citations

Life Sciences, Infectious Diseases, Microbiology +17

Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis

Amy Cutrell, Jonathan Schapiro, Carlo Federico Perno et al. · AIDS · 2021 · 201 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17